Business
Isodiol International Inc. Announces Plans to Enter Pet Industry with All-Natural CBD Supplement Line
Isodiol International Inc. Announces Plans to Enter Pet Industry with All-Natural CBD Supplement Line.
About this update from Isodiol International Inc
[{"type":"text","content":"\nIsodiol will commence sales in late November 2018, with the new functional CBD pet line, Pawceuticals.\n VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”) announced today it will be launching Pawceuticals, a CBD-based product line that naturally aids in restoring a pet’s health and improving overall wellness. The Pawceuticals functional CBD pet products are designed for dogs and cats and are scientifically formulated with a proprietary blend of adaptogens that may aid in comfort, calming, healthy gums support, immune support, itch support, joint support, kennel cough support, kidney support, liver support, urinary support and anti-aging. The Company anticipates these products will be available for purchase online in late November at Pawceuticals.com. “Pet owners are more passionate than ever about the health and wellness of their pets,” said CEO of Isodiol Marcos Agramont. “Pet owners today prefer products that are all natural and less harmful than standard veterinary prescribed medications. CBD offers powerful benefits especially when combined with other adaptogens to help maintain and improve a pet’s health and overall wellness without producing unwanted side effects.” Isodiol believes in providing all-natural CBD products to the public by continuously striving to create cutting-edge products that can offer happiness, health and protection for all members of the household, including pets. For more information on Isodiol, please visit www.isodiol.com About Isodiol International Inc. Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products and most recently received approval as having the first CBD designated as an Active Pharmaceutical Ingredient as was announced April 26, 2018. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding i...